Detalhe da pesquisa
1.
Fertility-sparing treatment for serous borderline ovarian tumors with extra-ovarian invasive implants: Analysis from the MITO14 study database.
Gynecol Oncol
; 165(2): 302-308, 2022 05.
Artigo
Inglês
| MEDLINE | ID: mdl-35232587
2.
CDKN1B mutation and copy number variation are associated with tumor aggressiveness in luminal breast cancer.
J Pathol
; 253(2): 234-245, 2021 02.
Artigo
Inglês
| MEDLINE | ID: mdl-33140857
3.
A European, Observational, Prospective Trial of Trabectedin Plus Pegylated Liposomal Doxorubicin in Patients with Platinum-Sensitive Ovarian Cancer.
Oncologist
; 26(4): e658-e668, 2021 04.
Artigo
Inglês
| MEDLINE | ID: mdl-33289956
4.
Fertility-sparing treatment in advanced-stage serous borderline ovarian tumors. An analysis from the MITO14 study database.
Gynecol Oncol
; 161(3): 825-831, 2021 06.
Artigo
Inglês
| MEDLINE | ID: mdl-33781554
5.
A TGF-ß associated genetic score to define prognosis and platinum sensitivity in advanced epithelial ovarian cancer.
Gynecol Oncol
; 156(1): 233-242, 2020 01.
Artigo
Inglês
| MEDLINE | ID: mdl-31711657
6.
Human epidermal growth factor receptor-2 (HER2) is a potential therapeutic target in extramammary Paget's disease of the vulva.
Int J Gynecol Cancer
; 30(11): 1672-1677, 2020 11.
Artigo
Inglês
| MEDLINE | ID: mdl-32998859
7.
Bevacizumab or PARP-Inhibitors Maintenance Therapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis.
Int J Mol Sci
; 21(11)2020 May 27.
Artigo
Inglês
| MEDLINE | ID: mdl-32471250
8.
Prognostic role of chemotherapy-induced neutropenia in first-line treatment of advanced ovarian cancer. A pooled analysis of MITO2 and MITO7 trials.
Gynecol Oncol
; 154(1): 83-88, 2019 07.
Artigo
Inglês
| MEDLINE | ID: mdl-31029508
9.
Identification of Novel Somatic TP53 Mutations in Patients with High-Grade Serous Ovarian Cancer (HGSOC) Using Next-Generation Sequencing (NGS).
Int J Mol Sci
; 19(5)2018 May 18.
Artigo
Inglês
| MEDLINE | ID: mdl-29783665
10.
Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trial.
Gynecol Oncol
; 144(1): 65-71, 2017 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-27871723
11.
Emesis and nausea related to single agent trabectedin in ovarian cancer patients: a sub-study of the MITO15 project.
Support Care Cancer
; 25(6): 1743-1748, 2017 06.
Artigo
Inglês
| MEDLINE | ID: mdl-28101677
12.
Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study.
Lancet Oncol
; 17(8): 1137-1146, 2016 08.
Artigo
Inglês
| MEDLINE | ID: mdl-27402147
13.
A microRNA signature defines chemoresistance in ovarian cancer through modulation of angiogenesis.
Proc Natl Acad Sci U S A
; 110(24): 9845-50, 2013 Jun 11.
Artigo
Inglês
| MEDLINE | ID: mdl-23697367
14.
Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial.
Lancet Oncol
; 15(4): 396-405, 2014 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-24582486
15.
Machine Learning Application Identifies Germline Markers of Hypertension in Patients With Ovarian Cancer Treated With Carboplatin, Taxane, and Bevacizumab.
Clin Pharmacol Ther
; 114(3): 652-663, 2023 09.
Artigo
Inglês
| MEDLINE | ID: mdl-37243926
16.
Weekly paclitaxel in heavily pretreated ovarian cancer patients: does this treatment still provide further advantages?
Arch Gynecol Obstet
; 285(2): 499-503, 2012 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-21735184
17.
An Exceptional Response to Dostarlimab in Mismatch Repair Deficient, Microsatellite Instability-High and Platinum Refractory Endometrial Cancer.
Curr Oncol
; 29(8): 5209-5212, 2022 07 22.
Artigo
Inglês
| MEDLINE | ID: mdl-35892982
18.
Surgical and medical treatment of clear cell ovarian cancer: results from the multicenter Italian Trials in Ovarian Cancer (MITO) 9 retrospective study.
Int J Gynecol Cancer
; 21(6): 1063-70, 2011 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-21633300
19.
Inhibition of CDK4/6 as Therapeutic Approach for Ovarian Cancer Patients: Current Evidences and Future Perspectives.
Cancers (Basel)
; 13(12)2021 Jun 17.
Artigo
Inglês
| MEDLINE | ID: mdl-34204543
20.
Multicenter phase 2 study of combined gemcitabine and epirubicin as second-line treatment for patients with advanced ovarian cancer.
Int J Gynecol Cancer
; 20(6): 953-7, 2010 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-20683401